/biz/ - Business & Finance

'm invested in $AEZS (4000 shares) that's working with a German university to produce a oral vaccine based on their existing Typhoid vaccine.

1. It's a pill so Long self life

2. It's a repurposed vaccine that's been proven to be safe.

3. No controversial RNA technology.

4. Since it's been already per-approved for another use the approval for Covid should be quick.

5. Shares are cheap,1.17 dollars a share & the company is on NASDAQ. 73.0 million shares in it's share structure compared to Pfizer's 5.5 billion shares.

>(NASDAQ:AEZS), signed an exclusive accord with University Wuerzburg. As per the terms of the agreement, Aetrena will evaluate the coronavirus vaccine developed by the University Wuerzburg, the leading university-based in Germany, for the protection against coronavirus.

>The typhoid fever vaccine is used as a carrier strain in the vaccine technology developed at University Wuerzburg. It will work as a SARS-CoV-2 LAB (live attenuated bacterial) vaccine for oral administration.

>The university Wuerzburg scheduled a meeting with the German authorities for the initial clinical study involving humans. If it finds sufficient scientific information for advancing into a clinical study, Aeterna will abbreviate the development program for the COVID-19 vaccine. The company is already has clinical safety data for Salmonella Typhi Ty21a, the underlying vaccine.

>CEO of Aeterna said the vaccines for coronavirus are already developed. The company plans to improve the vaccine to enhance its effectiveness, less stringent storage requirements, and make it more economical.

>The professor at The University Wuerzburg, Thomas Rudel said the new vaccine technology is based on the modified live-attenuated Salmonella Typhi Ty21a strain to offer two viral antigens.

>Also, incorporating dual antigens in one vaccine prevents the evolution of new variants of coronavirus.